CD151 表达降低与膀胱癌的晚期肿瘤分期有关。

Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer.

机构信息

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Pathology. 2012 Aug;44(5):448-52. doi: 10.1097/PAT.0b013e32835576ee.

DOI:10.1097/PAT.0b013e32835576ee

PMID:22772340

Abstract

AIMS

CD151 belongs to the group of tetraspanins and is aberrantly expressed in different tumours and differential expression has been associated with prognosis. The aim of this study was to clarify the relationship of CD151 expression with tumour phenotype and clinical outcome in bladder cancer.

METHODS

A bladder cancer tissue microarray containing samples from 686 urothelial bladder cancers was analysed by immunohistochemistry.

RESULTS

Membranous CD151 immunostaining was recorded in 409 (66.0%) of 620 analysable cases. High CD151 expression was seen in normal urothelium and in most non-invasive tumours. Low CD151 expression levels were associated with a more unfavourable tumour phenotype. CD151 staining was seen in 71.5% of 284 pTa, 62.1% of 145 pT1 and 60.4% of 187 pT2-4 cancers (p = 0.0033). CD151 staining was detectable in 77.3% of 75 grade 1, 71.1% of 273 grade 2 and 57.7% of 272 grade 3 cancers (p < 0.0001). CD151 expression status was not associated with overall or tumour-specific survival in muscle-invasive cancers (pT2-4), tumour progression in pT1 and recurrences in pTa tumours.

CONCLUSION

On the basis of our data we conclude that loss of CD151 may contribute to bladder cancer progression through attenuation of cell adhesion. In clinically defined subgroups CD151 expression does not provide additional prognostic information.

摘要

目的

CD151 属于四跨膜蛋白家族，在不同肿瘤中异常表达，其差异表达与预后相关。本研究旨在阐明 CD151 表达与膀胱癌肿瘤表型和临床结局的关系。

方法

采用免疫组织化学法分析包含 686 例尿路上皮膀胱癌样本的膀胱癌组织微阵列。

结果

在 620 例可分析病例中，有 409 例（66.0%）记录到膜性 CD151 免疫染色。高 CD151 表达见于正常尿路上皮和大多数非浸润性肿瘤。低 CD151 表达水平与更不利的肿瘤表型相关。284 例 pTa、145 例 pT1 和 187 例 pT2-4 肿瘤中 CD151 染色分别为 71.5%、62.1%和 60.4%（p=0.0033）。75 例 1 级、273 例 2 级和 272 例 3 级肿瘤中 CD151 染色分别为 77.3%、71.1%和 57.7%（p<0.0001）。CD151 表达状态与肌层浸润性癌症（pT2-4）、pT1 肿瘤进展和 pTa 肿瘤复发的总生存或肿瘤特异性生存无关。